ERYTECH Announces the Hosting of a KOL Event as the TRYbeCA-1 Phase 3 Trial in Second-line Pancreatic Cancer Nears Complete Enrollment
More than 450 of the planned ~500 patients enrolledInterim superiority analysis expected around year-end 2020Call with KOL Dr. Manuel Hidalgo […]